Loading...
Loading...
Baxter International Inc.
BAX and Coherus Biosciences, Inc. today
announced that they have entered into an exclusive collaboration to develop
and commercialize a biosimilar to etanercept for Europe, Canada, Brazil and
certain other markets. Additionally, the agreement allows for the expansion of
the collaboration to include another product. Biosimilars are intended to be
used in place of existing, branded biologics to treat a range of chronic and
often life-threatening diseases and have the potential to reduce costs and
expand patient access.
Under the agreement, Baxter will make an upfront payment of $30 million.
Coherus will conduct development and Baxter will make payments of up to $216
million contingent upon the achievement of development and regulatory events.
The agreement also allows for development and commercialization of an
alternative biosimilar to etanercept, pending the outcome of clinical data.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in